Related Experiment Video
Updated: Aug 3, 2026
Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
Published on: August 2, 2018
Association of improved cardiac function in donors with C34T mutation of the AMP deaminase 1 gene
A H Y Yuen1, M H Yacoub, E J Birks
1Heart Science Centre, Imperial College at Harefield Hospital, Harefield, Middlesex, UK. ada.yuen@imperial.ac.uk
Insights
The C34T mutation in the AMPD1 gene did not differ between heart failure patients and controls. However, this mutation was more frequent in healthy donor hearts than in controls or failing hearts.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
Background:
- The C34T mutation in the AMP deaminase (AMPD1) gene is linked to better outcomes in ischemic heart disease.
- Understanding the mutation's prevalence in different cardiac states is crucial.
Purpose of the Study:
- To investigate the frequency of the AMPD1 C34T mutation in hearts with varying cardiac function.
- To compare mutation prevalence between heart failure patients, healthy controls, and healthy donor hearts.
Main Methods:
- Genotyping analysis was performed to detect the C34T mutation.
- Mutation frequency was assessed in three groups: patients with heart failure, healthy individuals, and healthy heart donors.
Main Results:
- No significant difference in AMPD1 C34T mutation frequency was observed between heart failure patients and healthy controls.
- A significantly higher frequency of the AMPD1 C34T mutation was found in healthy donor hearts compared to both healthy controls and donors with failing hearts.
Conclusions:
- The AMPD1 C34T mutation's prevalence does not correlate with heart failure status in the studied cohorts.
- The elevated frequency in healthy donor hearts suggests a potential protective role or specific population distribution that warrants further investigation.
Abstract:
Possession of the C34T mutation in AMP deaminase (AMPD1) gene has been shown to be associated with attenuation of the progression of heart failure and improved survival in ischemic heart disease. In this study, we examined the frequency of the mutation in the heart with good and poor cardiac function and in healthy controls. We found that there was no difference in the frequency of the mutation between the patients with heart failure and healthy controls. However, the frequency of the mutation in the healthy donor hearts was much higher when compared to healthy controls or donors with failing hearts.
